US20090118227A1 - Carotenoid-containing compositions and methods - Google Patents

Carotenoid-containing compositions and methods Download PDF

Info

Publication number
US20090118227A1
US20090118227A1 US12/206,838 US20683808A US2009118227A1 US 20090118227 A1 US20090118227 A1 US 20090118227A1 US 20683808 A US20683808 A US 20683808A US 2009118227 A1 US2009118227 A1 US 2009118227A1
Authority
US
United States
Prior art keywords
nutritional composition
carotene
astaxanthin
beta
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/206,838
Inventor
Zeina Jouni
Zeina Makhoul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mead Johnson Nutrition Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to US12/206,838 priority Critical patent/US20090118227A1/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JOUNI, ZEINA, MAKHOUL, ZEINA
Assigned to MJN RESTRUCTURING HOLDCO, INC. reassignment MJN RESTRUCTURING HOLDCO, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRISTOL-MYERS SQUIBB COMPANY
Assigned to MEAD JOHNSON NUTRITION COMPANY reassignment MEAD JOHNSON NUTRITION COMPANY MERGER (SEE DOCUMENT FOR DETAILS). Assignors: MJN RESTRUCTURING HOLDCO, INC.
Publication of US20090118227A1 publication Critical patent/US20090118227A1/en
Priority to US13/486,760 priority patent/US9072314B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/40—Colouring or decolouring of foods
    • A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
    • A23L5/43—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
    • A23L5/44—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates generally to carotenoid-containing compositions, methods for inhibiting the growth of pathogenic bacteria, and methods for preventing or treating a bacterial infection in a subject via the administration of carotenoids.
  • H. pylori bacteria Approximately two-thirds of the world's population is infected with Helicobacter pylori bacteria. Many people that are infected with the bacteria never suffer any symptoms related to the infection. In some cases, however, H. pylori infection can cause chronic active, chronic persistent, or atrophic gastritis. Infection with H. pylori also causes duodenal and gastric ulcers. In fact, H. pylori causes more than 90% of duodenal ulcers and 80% of gastric ulcers. The infection has additionally been associated with dyspepsia, iron-deficient anemia, and gastric malignancy.
  • Helicobacter pylori which was previously known as Campylobacter pylori, is a gram-negative, spiral-shaped bacterium. It protects itself from the harsh acidic environment of the stomach by covering itself with the mucus of the stomach. Once covered, it is able to fight any stomach acid that does reach it with urease, an enzyme it possesses. Once nestled within the stomach mucus, H. pylori is able to penetrate the protective lining of the stomach, induce inflammatory cytokines, and cause gastric inflammation.
  • H. pylori It is not currently known how H. pylori is transmitted or why some people become symptomatic while others do not.
  • the bacteria are most likely spread from person to person through fecal-oral or oral-oral routes. Contaminated water or food sources may also contribute to the transmission of the bacteria.
  • H. pylori infection in infants and children is particularly important, as the incidence of H. pylori infection is greatest in childhood, particularly in developing countries where infection rates can be as high as 50% by age 5 years. Precise estimates of the age of acquisition of the invention are difficult to obtain because most children that are infected are asymptomatic. Even without symptoms, however, the infection can develop into more dangerous conditions such as antral gastritis, the most common manifestation in children. In addition, if an individual becomes infected with H. pylori during childhood, the infection may remain in his system throughout the course of his life, potentially leading to other diseases in adulthood.
  • H. pylori infection currently consists of 10 days to 2 weeks of antibiotic treatment, such as with amoxicillin, tetracycline, metronidazole, or clarithromycin, plus either ranitidine bismuth citrate, bismuth subsalicylate, or a proton pump inhibitor.
  • antibiotic treatment such as with amoxicillin, tetracycline, metronidazole, or clarithromycin, plus either ranitidine bismuth citrate, bismuth subsalicylate, or a proton pump inhibitor.
  • the disadvantage to widespread antibiotic treatment is the development of antibiotic resistance.
  • the H. pylori infection has previously been shown to be resistant to several antibiotic treatments, contributing to treatment failure in a number of cases.
  • the present invention is directed to a nutritional composition
  • a nutritional composition comprising astaxanthin, beta-carotene, galacto-oligosaccharide, and polydextrose.
  • the invention is directed to a method for inhibiting the growth of pathogenic bacteria in a subject comprising administering to the subject an effective amount of astaxanthin and beta-carotene.
  • the invention is additionally directed to a method for inhibiting the growth of H. pylori in an infant comprising administering to the infant an infant formula containing an effective amount of astaxanthin and beta-carotene.
  • the invention is directed to a method for preventing or treating a bacterial infection or preventing obesity in a subject comprising administering to the subject a nutritional composition comprising astaxanthin, beta-carotene, galacto-oligosaccharide, and polydextrose.
  • Carotenoids are a related group of greater than 600 natural compounds, irrespective of geometric and stereoisomers, with demonstrated antioxidant efficacy.
  • the carotenoids are broadly divided into “carotenes,” or non-oxygen substituted hydrocarbon carotenoids, and “xanthophylls,” oxygen-substituted carotenoids. Between 500 and 600 carotenoids have been identified, of which only about 24 occur in human foodstuffs.
  • the major carotenoids found in foods are ⁇ -carotene, ⁇ -carotene, lycopene, lutein, zeaxanthin, and ⁇ -cryptoxanthin.
  • carotenoids are present in foods such as carrots, pumpkins, sweet potatoes, tomatoes, and other deep green, yellow, orange, red fruits and vegetables. Most carotenoids occur in nature predominantly in the all-trans form. Three of these carotenoids, ⁇ -carotene, ⁇ -carotene and ⁇ -cryptoxanthin, can be converted into retinol and are therefore considered provitamin A carotenoids. Lycopene, lutein and zeaxanthin do not have a vitamin A function and are referred to as nonprovitamin A carotenoids.
  • carotenoids An important feature of carotenoids is a centrally located, extended conjugated double-bond system, which is responsible for the chemical reactivity, light-absorbing properties, and, thus, the color of carotenoids.
  • Potential biological function is determined by the chemical structure of carotenoids.
  • the alternating single and double bond of the polyene backbone of carotenoids allow them to absorb excess energy from other molecules, which accounts for their antioxidant properties. They perform their antioxidant function by either quenching singlet oxygen and/or blocking free radical-mediated reactions.
  • the polarity of the specific end groups of carotenoids accounts for the differences in how they interact with biological membranes. Carotenoids are associated with lipid portions of human tissues, cells, and membranes and bind to hydrophobic surfaces because they are lipophilic. In addition, carotenoids are easily isomerized and oxidized due to their high unsaturation and hence may lose biological activity after processing and storage.
  • carotenoids have received the interest of researchers from diverse fields including food science, pharmacy, biochemistry and nutrition because of their wide spectrum of biological functions such as provitamin A, antioxidant, immuno-enhancement, and prevention of degenerative diseases.
  • the technical problem to be solved by the present invention is to provide novel carotenoid nutritional compositions that are useful in inhibiting the growth of pathogenic bacteria and/or preventing or treating bacterial infections in subjects.
  • the present invention is directed to a nutritional composition comprising astaxanthin, beta-carotene, galacto-oligosaccharide, and polydextrose.
  • the present invention is also directed, in an embodiment, to a method for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administering to them an effective amount of astaxanthin and beta-carotene.
  • Astaxanthin is a fat-soluble, oxygenated pigment which is classified as a xanthophyll and is a member of the carotenoid family. It has a unique molecular structure that gives it powerful antioxidant function. It can be extracted from salmon, microalgae, and Pfaffia, a yeast. Current research shows that due to astaxanthin's potent antioxidant activity, it may be beneficial in cardiovascular, immune, anti-inflammatory, and neurodegenerative diseases.
  • its varied actions include: inhibition of lipid peroxidation at the cell level; crossing the blood-brain barrier, effecting treatment of ocular and neurodegenerative diseases such as glaucoma and Alzheimer's; entrapment of free radicals by adding them to its long, double-bonded chain rather than donating an electron; stabilization of the cell membrane via its polar end groups spanning the cell membrane and increasing its rigidity and mechanical strength; neutralization of singlet and triplet oxygen (de-charges) generated by UVA and UVB radiation and other sources; binding to a lipoprotein, an efficient transport vehicle, making it more bioavailable; increase of immune system function including heightened production of antibody-secreting cells and Interleukin 2 and suppression of Interferon-gamma; inhibition of reactive oxygen species that cause inflammation; enhancing of the antioxidant actions of Vitamin E and Vitamin C; and encouraging the release of Vitamin A from the liver when needed.
  • Astaxanthin provides significantly more antioxidant capacity than other carotenoids and antioxidants such as beta-carotene and Vitamin E. In fact, Astaxanthin has 100-500 times the antioxidant capacity of Vitamin E and 10 times the antioxidant capacity of beta-carotene. Many laboratory studies also indicate astaxanthin is a stronger antioxidant than lutein, lycopene and tocotrienols. Astaxanthin is often added to food products or nutritional supplements for its antioxidant effects.
  • the effective amount of astaxanthin is within the range of about 0.01 mg and about 10 mg per kg body weight per day. In another embodiment of the invention, the effective amount of astaxanthin is within the range of about 0.1 mg and about 5 mg per kg body weight per day. In a particular embodiment of the invention, the effective amount of astaxanthin is about 1 mg per kg body weight per day.
  • beta-carotene is a carotenoid. Beta-carotene is the most common of the carotenes and can be found in yellow, orange, and green leafy fruits and vegetables. It is unclear whether beta-carotene has any biological function for humans other than as a precursor for vitamin A. There is some evidence that beta-carotene may play a beneficial role in human nutrition beyond its provitamin A function. Beta-carotene has antioxidant activity, at least in vitro, and it may enhance intercellular communication and may have immunomodulatory and anticarcinogenic activities in certain circumstances.
  • beta-carotene The structure of beta-carotene is set forth below:
  • the effective amount of beta-carotene is within the range of about 0.01 mg and about 10 mg per kg body weight per day. In another embodiment of the invention, the effective amount of beta-carotene is within the range of about 0.1 mg and about 5 mg per kg body weight per day. In a particular embodiment of the invention, the effective amount of beta-carotene is about 1 mg per kg body weight per day.
  • the source of either astaxanthin or beta-carotene can be any source known in the art such as plant material, seafood, and/or single cell.
  • either of astaxanthin or beta-carotene may be in raw form or may be chemically manipulated.
  • either of astaxanthin or beta-carotene may be genetically modified organisms.
  • the present invention is directed, in certain embodiments, methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administering to them an effective amount of astaxanthin and beta-carotene.
  • the pathogenic bacteria which experience growth inhibition as a result of the invention may be any pathogenic bacteria known in the art.
  • the pathogenic bacteria is H. pylori.
  • the bacterial infection of the invention may be any known in the art, but in a particular embodiment, is H. pylori infection.
  • the astaxanthin and beta carotene may be administered in the form of a nutritional composition, infant formula, human milk supplement, or children's nutritional product.
  • infant formula means a composition that satisfies the nutrient requirements of an infant by being a substitute for human milk.
  • the method of the invention is useful in preventing or treating bacterial infections in human infants, children, or adults.
  • the infant formula may be nutritionally complete and contain suitable types and amounts of lipid, carbohydrate, protein, vitamins and minerals.
  • the amount of lipid or fat typically can vary from about 3 to about 7 g/100 kcal.
  • the amount of protein typically can vary from about 1 to about 5 g/100 kcal.
  • the amount of carbohydrate typically can vary from about 8 to about 12 g/100 kcal.
  • Protein sources can be any used in the art, e.g., nonfat milk, whey protein, casein, soy protein, hydrolyzed protein, and/or amino acids.
  • Carbohydrate sources can be any used in the art, e.g., lactose, glucose, corn syrup solids, maltodextrins, sucrose, starch, and/or rice syrup solids.
  • Lipid sources can be any used in the art, e.g., vegetable oils such as palm oil, canola oil, corn oil, soybean oil, palmolein, coconut oil, medium chain triglyceride oil, high oleic sunflower oil, and/or high oleic safflower oil.
  • Enfalac, Enfamil®, Enfamil® Premature Formula, Enfamil® with Iron, Enfamil® LIPIL®, Lactofree®, Nutramigen®, Pregestimil®, and ProSobee® may be supplemented with suitable levels of astaxanthin and beta-carotene and used in practice of the invention.
  • the amounts of each carotenoid in the formula may be up to about 40 nmol/g fat. In another embodiment, the amounts of each carotenoid in the formula may be within the range of about 2 nmol/g and about 35 nmol/g fat. In a particular embodiment, the amounts of each carotenoid in the formula may be within the range of about 5 nmol/g and about 30 nmol/g fat.
  • the total carotenoid blend may comprise, in an embodiment, up to about 2000 mcg/L infant formula. In other embodiments, the total carotenoid blend may comprise from about 100 to about 1500 mcg/L infant formula. In yet another embodiment, the total carotenoid blend may comprise from about 200 to about 1200 mcg/L infant formula.
  • the individual carotenoids may be present in the infant formula in an amount of from about 50 to about 1150 mcg/L, about 75 to about 230 mcg/L, or about 100 to about 200 mcg/L.
  • additional components may be administered in combination with astaxanthin and beta-carotene.
  • additional components may include probiotics, prebiotics, or long chain polyunsaturated fatty acids (LCPUFAs).
  • the components may be administered separately from the astaxanthin and beta-carotene or may be included as part of a nutritional composition, infant formula, human milk supplement, or children's nutritional product that contains astaxanthin, beta-carotene, and one or more additional components.
  • probiotic means a microorganism that exerts beneficial effects on the health of the host. Any probiotic known in the art may be used, provided it is suitable for combination with the other components of the supplement.
  • the probiotic may be chosen from the group consisting of Lactobacillus and Bifidobacterium.
  • the probiotic can be Lactobacillus rhamnosus GG.
  • prebiotic means a non-digestible food ingredient that stimulates the growth and/or activity of probiotics.
  • any prebiotic known in the art may be used, provided it is suitable for combination with the other components of the supplement.
  • the prebiotic can be selected from the group consisting of fructo-oligosaccharide, gluco-oligosaccharide, galacto-oligosaccharide, inulin, isomalto-oligosaccharide, polydextrose, xylo-oligosaccharide, lactulose, and combinations thereof.
  • the prebiotic is a mixture of galacto-oligosaccharide and polydextrose.
  • the total amount of prebiotics present in the nutritional composition may be from about 1.0 g/L to about 10.0 g/L of the composition. In another embodiment, the total amount of prebiotics present in the nutritional composition may be from about 2.0 g/L and about 8.0 g/L of the composition. In yet another embodiment, the total amount of prebiotics present in the nutritional composition may be about 4.0 g/L of the composition.
  • the amount of galacto-oligosaccharide in the nutritional composition may, in an embodiment, be within the range of from about 1.0 g/L to about 4.0 g/L. In another embodiment, the amount of galacto-oligosaccharide in the nutritional composition may be about 2.0 g/L. If polydextrose is used as a prebiotic, the amount of polydextrose in the nutritional composition may, in an embodiment, be within the range of from about 1.0 g/L to about 4.0 g/L. In another embodiment, the amount of polydextrose in the nutritional composition may be about 2.0 g/L.
  • galacto-oligosaccharide and polydextrose are supplemented into the nutritional composition in a total amount of about 4.0 g/L.
  • the amount of galacto-oligosaccharide may be about 2.0 g/L and the amount of polydextrose may be about 2.0 g/L.
  • prebiotics and carotenoids may provide a synergistic effect. More specifically, it is believed that the prebiotic may alter the composition of the gut flora to provide a greater number of beneficial bacteria and fewer pathogenic bacteria, further contributing to the antimicrobial effect of the carotenoids in the present invention.
  • LCPUFAs may be administered in combination with astaxanthin and beta-carotene.
  • the LCPUFAs may include docosahexaenoic acid (DHA), arachidonic acid (ARA), and/or eicosapentaenoic acid (EPA).
  • DHA docosahexaenoic acid
  • ARA arachidonic acid
  • EPA eicosapentaenoic acid
  • the weight ratio of ARA:DHA may be from about 1:3 to about 9:1. In one embodiment of the present invention, this ratio is from about 1:2 to about 4:1. In yet another embodiment, the ratio is from about 2:3 to about 2:1. In one particular embodiment the ratio is about 2:1. In another particular embodiment of the invention, the ratio is about 1:1.5. In other embodiments, the ratio is about 1:1.3. In still other embodiments, the ratio is about 1:1.9. In a particular embodiment, the ratio is about 1.5:1. In a further embodiment, the ratio is about 1.47:1.
  • the level of DHA may be within the range of about 0.0% and about 1.00% of fatty acids, by weight. In other embodiments, the level of DHA may be about 0.32% by weight. In some embodiments, the level of DHA may be about 0.33% by weight. In another embodiment, the level of DHA may be about 0.64% by weight. In another embodiment, the level of DHA may be about 0.67% by weight. In yet another embodiment, the level of DHA may be about 0.96% by weight. In a further embodiment, the level of DHA may be about 1.00% by weight.
  • the level of ARA may be within the range of 0.0% and 0.67% of fatty acids, by weight. In another embodiment, the level of ARA may be about 0.67% by weight. In another embodiment, the level of ARA may be about 0.5% by weight. In yet another embodiment, the level of DHA may be within the range of about 0.47% and about 0.48% by weight.
  • the amount of DHA may be from about 2 mg/100 kilocalories (kcal) to about 100 mg/100 kcal. In another embodiment, the amount of DHA may be from about 5 mg/100 kcal to about 75 mg/100 kcal. In yet another embodiment, the amount of DHA may be from about 15 mg/100 kcal to about 60 mg/100 kcal.
  • the amount of ARA may be from about 4 mg/100 kilocalories (kcal) to about 100 mg/100 kcal. In another embodiment, the amount of ARA may be from about 10 mg/100 kcal to about 67 mg/100 kcal. In yet another embodiment, the amount of ARA may be from about 20 mg/100 kcal to about 50 mg/100 kcal. In a particular embodiment, the amount of ARA may be from about 25 mg/100 kcal to about 40 mg/100 kcal. In one embodiment, the amount of ARA is about 30 mg/100 kcal.
  • the effective amount of DHA may be from about 3 mg per kg of body weight per day to about 150 mg per kg of body weight per day. In one embodiment of the invention, the amount is from about 6 mg per kg of body weight per day to about 100 mg per kg of body weight per day. In another embodiment the amount is from about 15 mg per kg of body weight per day to about 60 mg per kg of body weight per day.
  • the effective amount of ARA may be from about 5 mg per kg of body weight per day to about 150 mg per kg of body weight per day. In one embodiment of this invention, the amount varies from about 10 mg per kg of body weight per day to about 120 mg per kg of body weight per day. In another embodiment, the amount varies from about 15 mg per kg of body weight per day to about 90 my per kg of body weight per day. In yet another embodiment, the amount varies from about 20 mg per kg of body weight per day to about 60 mg per kg of body weight per day.
  • composition of the invention is supplemented with oils containing LCPUFAs, it may be accomplished using standard techniques known in the art. For example, an equivalent amount of an oil which is normally present in a composition, such as high oleic sunflower oil, may be replaced with the LCPUFAs.
  • the source of the LCPUFAs can be any source known in the art such as marine oil, fish oil, single cell oil, egg yolk lipid, and/or brain lipid.
  • the LCPUFAs can be in natural form or refined form.
  • astaxanthin and beta-carotene may be combined and administered to a subject for the purpose of treating or preventing any of the following: reflux, spitting up, abdominal pain, bloating, vomiting, gastric inflammation, gastritis, ulcer formation, hypertension, dyslipidemia, Type I and II diabetes, insulin sensitivity, obesity, cardiovascular disease, cancer, atherosclerosis.
  • astaxanthin and beta-carotene can be combined and administered for the purpose of improving digestion or stool consistency, modulating antioxidant enzymes, decreasing cellular and tissue oxidative stress, shifting T-helper cell Types 1 to Th2 balance, and modulating immune function.
  • the invention includes a method for improving weight management in a subject comprising administering to the subject an effective amount of astaxanthin and beta-carotene. In other embodiments, the invention includes a method for preventing or treating obesity in a subject comprising administering to the subject an effective amount of astaxanthin and beta-carotene.
  • Obesity has been linked with an inflammation of adipose tissue. In some studies, inflammation has also been identified as an early characteristic of obesity.
  • the combination of astaxanthin and beta-carotene, in addition to their antioxidant benefits, may contribute to a reduction in inflammation, thereby reducing or preventing the onset of obesity in the present invention.
  • the invention is directed to the use of a combination of astaxanthin and beta-carotene in the manufacture of an ingestible composition for inhibiting the growth of pathogenic bacterial in a subject.
  • the invention is directed to the use of a combination of astaxanthin and beta-carotene in the manufacture of an ingestible composition for inhibiting the growth of H. pylori in an infant.
  • the invention is directed to the use of a combination of astaxanthin and beta-carotene in the manufacture of an ingestible composition for preventing or treating a bacterial infection in a subject.
  • the invention is directed to the use of a combination of astaxanthin and beta-carotene in the manufacture of an ingestible composition for preventing obesity in a subject.
  • the invention in an embodiment, is also directed to a combination of astaxanthin and beta-carotene for use in inhibiting the growth of pathogenic bacteria in a subject.
  • the invention is also directed, in an embodiment, to a combination of astaxanthin and beta-carotene for use in inhibiting the growth of H. pylori in an infant.
  • the invention is directed, in an embodiment, to a combination of astaxanthin and beta-carotene for use in preventing or treating a bacterial infection in a subject.

Abstract

The present invention is directed to carotenoid compositions and methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administration of an effective amount of astaxanthin and beta-carotene.

Description

    CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
  • This application claims the priority benefit of U.S. Provisional Application No. 60/986,029, filed Nov. 7, 2007, which is incorporated by reference herein in its entirety.
    • BACKGROUND OF THE INVENTION
  • (1) Field of the Invention
  • The present invention relates generally to carotenoid-containing compositions, methods for inhibiting the growth of pathogenic bacteria, and methods for preventing or treating a bacterial infection in a subject via the administration of carotenoids.
  • (2) Description of the Related Art
  • Approximately two-thirds of the world's population is infected with Helicobacter pylori bacteria. Many people that are infected with the bacteria never suffer any symptoms related to the infection. In some cases, however, H. pylori infection can cause chronic active, chronic persistent, or atrophic gastritis. Infection with H. pylori also causes duodenal and gastric ulcers. In fact, H. pylori causes more than 90% of duodenal ulcers and 80% of gastric ulcers. The infection has additionally been associated with dyspepsia, iron-deficient anemia, and gastric malignancy. Further, approximately 15% of infected individuals will at some time develop peptic ulcer disease or gastric adenocarcinoma, which is the second most common cause of cancer deaths worldwide. Solnick, et al., Natural Acquisition of Helicobacter pylori Infection in Newborn Rhesus Macaques, J. Clin. Microbio. 41(12): 5511-5516 (2003).
  • Helicobacter pylori, which was previously known as Campylobacter pylori, is a gram-negative, spiral-shaped bacterium. It protects itself from the harsh acidic environment of the stomach by covering itself with the mucus of the stomach. Once covered, it is able to fight any stomach acid that does reach it with urease, an enzyme it possesses. Once nestled within the stomach mucus, H. pylori is able to penetrate the protective lining of the stomach, induce inflammatory cytokines, and cause gastric inflammation.
  • It is not currently known how H. pylori is transmitted or why some people become symptomatic while others do not. The bacteria are most likely spread from person to person through fecal-oral or oral-oral routes. Contaminated water or food sources may also contribute to the transmission of the bacteria.
  • The avoidance of H. pylori infection in infants and children is particularly important, as the incidence of H. pylori infection is greatest in childhood, particularly in developing countries where infection rates can be as high as 50% by age 5 years. Precise estimates of the age of acquisition of the invention are difficult to obtain because most children that are infected are asymptomatic. Even without symptoms, however, the infection can develop into more dangerous conditions such as antral gastritis, the most common manifestation in children. In addition, if an individual becomes infected with H. pylori during childhood, the infection may remain in his system throughout the course of his life, potentially leading to other diseases in adulthood.
  • Treatment for H. pylori infection currently consists of 10 days to 2 weeks of antibiotic treatment, such as with amoxicillin, tetracycline, metronidazole, or clarithromycin, plus either ranitidine bismuth citrate, bismuth subsalicylate, or a proton pump inhibitor. The disadvantage to widespread antibiotic treatment is the development of antibiotic resistance. The H. pylori infection has previously been shown to be resistant to several antibiotic treatments, contributing to treatment failure in a number of cases. F Mégraud, H pylori Antibiotic Resistance: Prevalence, Importance, and Advances in Testing, Gut 53: 1374-1384 (2004). In a particular study, 29% of the H. pylori strains tested were resistant to clarithromycin, 24% to metronidazole, and 10% were resistant to both clarithromycin and metronidazole. Kato, et al., Antibiotic Resistance of Helicobacter pylori Strains in Japanese Children, J. Clin. Microbio. 40(2): 649-653 (2002). Thus, infected individuals cannot be assured that antibiotic treatment will be effective.
  • Therefore, a need remains for a method for preventing or treating H. pylori infection in subjects. It would also be beneficial to provide a method for achieving such prevention or treatment through the use of compositions other than traditional antibiotics.
    • SUMMARY OF THE INVENTION
  • Briefly, therefore, the present invention is directed to a nutritional composition comprising astaxanthin, beta-carotene, galacto-oligosaccharide, and polydextrose.
  • In another embodiment, the invention is directed to a method for inhibiting the growth of pathogenic bacteria in a subject comprising administering to the subject an effective amount of astaxanthin and beta-carotene.
  • The invention is additionally directed to a method for inhibiting the growth of H. pylori in an infant comprising administering to the infant an infant formula containing an effective amount of astaxanthin and beta-carotene.
  • In other embodiments, the invention is directed to a method for preventing or treating a bacterial infection or preventing obesity in a subject comprising administering to the subject a nutritional composition comprising astaxanthin, beta-carotene, galacto-oligosaccharide, and polydextrose.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Reference now will be made in detail to the embodiments of the invention, one or more examples of which are set forth below. Each example is provided by way of explanation of the invention, not a limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, can be used on another embodiment to yield a still further embodiment.
  • Thus, it is intended that the present invention covers such modifications and variations as come within the scope of the appended claims and their equivalents. Other objects, features and aspects of the present invention are disclosed in or are obvious from the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not intended as limiting the broader aspects of the present invention.
  • Carotenoids are a related group of greater than 600 natural compounds, irrespective of geometric and stereoisomers, with demonstrated antioxidant efficacy. The carotenoids are broadly divided into “carotenes,” or non-oxygen substituted hydrocarbon carotenoids, and “xanthophylls,” oxygen-substituted carotenoids. Between 500 and 600 carotenoids have been identified, of which only about 24 occur in human foodstuffs. The major carotenoids found in foods are α-carotene, β-carotene, lycopene, lutein, zeaxanthin, and β-cryptoxanthin. They are present in foods such as carrots, pumpkins, sweet potatoes, tomatoes, and other deep green, yellow, orange, red fruits and vegetables. Most carotenoids occur in nature predominantly in the all-trans form. Three of these carotenoids, α-carotene, β-carotene and β-cryptoxanthin, can be converted into retinol and are therefore considered provitamin A carotenoids. Lycopene, lutein and zeaxanthin do not have a vitamin A function and are referred to as nonprovitamin A carotenoids.
  • An important feature of carotenoids is a centrally located, extended conjugated double-bond system, which is responsible for the chemical reactivity, light-absorbing properties, and, thus, the color of carotenoids. Potential biological function is determined by the chemical structure of carotenoids. The alternating single and double bond of the polyene backbone of carotenoids allow them to absorb excess energy from other molecules, which accounts for their antioxidant properties. They perform their antioxidant function by either quenching singlet oxygen and/or blocking free radical-mediated reactions. The polarity of the specific end groups of carotenoids accounts for the differences in how they interact with biological membranes. Carotenoids are associated with lipid portions of human tissues, cells, and membranes and bind to hydrophobic surfaces because they are lipophilic. In addition, carotenoids are easily isomerized and oxidized due to their high unsaturation and hence may lose biological activity after processing and storage.
  • In recent years, carotenoids have received the interest of researchers from diverse fields including food science, pharmacy, biochemistry and nutrition because of their wide spectrum of biological functions such as provitamin A, antioxidant, immuno-enhancement, and prevention of degenerative diseases.
  • For example, see U.S. Pat. No. 7,090,879 to Albrecht, et al., U.S. Pat. No. 6,268,450 to Asami, et al., U.S. Pat. No. 6,727,373 to Bijl, et al., U.S. Patent App. Pub. No. 2003/0175364 to Newman, et al, or U.S. Patent App. Pub. No. 2006/0068019 to Dalziel, et al.
  • The technical problem to be solved by the present invention is to provide novel carotenoid nutritional compositions that are useful in inhibiting the growth of pathogenic bacteria and/or preventing or treating bacterial infections in subjects. Thus, in an embodiment, the present invention is directed to a nutritional composition comprising astaxanthin, beta-carotene, galacto-oligosaccharide, and polydextrose. The present invention is also directed, in an embodiment, to a method for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administering to them an effective amount of astaxanthin and beta-carotene.
  • Astaxanthin is a fat-soluble, oxygenated pigment which is classified as a xanthophyll and is a member of the carotenoid family. It has a unique molecular structure that gives it powerful antioxidant function. It can be extracted from salmon, microalgae, and Pfaffia, a yeast. Current research shows that due to astaxanthin's potent antioxidant activity, it may be beneficial in cardiovascular, immune, anti-inflammatory, and neurodegenerative diseases. Specifically, its varied actions include: inhibition of lipid peroxidation at the cell level; crossing the blood-brain barrier, effecting treatment of ocular and neurodegenerative diseases such as glaucoma and Alzheimer's; entrapment of free radicals by adding them to its long, double-bonded chain rather than donating an electron; stabilization of the cell membrane via its polar end groups spanning the cell membrane and increasing its rigidity and mechanical strength; neutralization of singlet and triplet oxygen (de-charges) generated by UVA and UVB radiation and other sources; binding to a lipoprotein, an efficient transport vehicle, making it more bioavailable; increase of immune system function including heightened production of antibody-secreting cells and Interleukin 2 and suppression of Interferon-gamma; inhibition of reactive oxygen species that cause inflammation; enhancing of the antioxidant actions of Vitamin E and Vitamin C; and encouraging the release of Vitamin A from the liver when needed.
  • Astaxanthin provides significantly more antioxidant capacity than other carotenoids and antioxidants such as beta-carotene and Vitamin E. In fact, Astaxanthin has 100-500 times the antioxidant capacity of Vitamin E and 10 times the antioxidant capacity of beta-carotene. Many laboratory studies also indicate astaxanthin is a stronger antioxidant than lutein, lycopene and tocotrienols. Astaxanthin is often added to food products or nutritional supplements for its antioxidant effects.
  • The structure of astaxanthin is shown below:
  • Figure US20090118227A1-20090507-C00001
  • In an embodiment of the invention, the effective amount of astaxanthin is within the range of about 0.01 mg and about 10 mg per kg body weight per day. In another embodiment of the invention, the effective amount of astaxanthin is within the range of about 0.1 mg and about 5 mg per kg body weight per day. In a particular embodiment of the invention, the effective amount of astaxanthin is about 1 mg per kg body weight per day.
  • Like astaxanthin, beta-carotene is a carotenoid. Beta-carotene is the most common of the carotenes and can be found in yellow, orange, and green leafy fruits and vegetables. It is unclear whether beta-carotene has any biological function for humans other than as a precursor for vitamin A. There is some evidence that beta-carotene may play a beneficial role in human nutrition beyond its provitamin A function. Beta-carotene has antioxidant activity, at least in vitro, and it may enhance intercellular communication and may have immunomodulatory and anticarcinogenic activities in certain circumstances.
  • The structure of beta-carotene is set forth below:
  • Figure US20090118227A1-20090507-C00002
  • In an embodiment of the invention, the effective amount of beta-carotene is within the range of about 0.01 mg and about 10 mg per kg body weight per day. In another embodiment of the invention, the effective amount of beta-carotene is within the range of about 0.1 mg and about 5 mg per kg body weight per day. In a particular embodiment of the invention, the effective amount of beta-carotene is about 1 mg per kg body weight per day.
  • As used in the present invention, the source of either astaxanthin or beta-carotene can be any source known in the art such as plant material, seafood, and/or single cell. In certain embodiments, either of astaxanthin or beta-carotene may be in raw form or may be chemically manipulated. In a particular embodiment, either of astaxanthin or beta-carotene may be genetically modified organisms.
  • As noted, the present invention is directed, in certain embodiments, methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administering to them an effective amount of astaxanthin and beta-carotene. The pathogenic bacteria which experience growth inhibition as a result of the invention may be any pathogenic bacteria known in the art. In a particular embodiment, the pathogenic bacteria is H. pylori. Likewise, the bacterial infection of the invention may be any known in the art, but in a particular embodiment, is H. pylori infection.
  • In an embodiment, the astaxanthin and beta carotene may be administered in the form of a nutritional composition, infant formula, human milk supplement, or children's nutritional product. As used herein, the term “infant formula” means a composition that satisfies the nutrient requirements of an infant by being a substitute for human milk. Thus, the method of the invention is useful in preventing or treating bacterial infections in human infants, children, or adults.
  • If the astaxanthin and beta-carotene are administered via an infant formula, the infant formula may be nutritionally complete and contain suitable types and amounts of lipid, carbohydrate, protein, vitamins and minerals. The amount of lipid or fat typically can vary from about 3 to about 7 g/100 kcal. The amount of protein typically can vary from about 1 to about 5 g/100 kcal. The amount of carbohydrate typically can vary from about 8 to about 12 g/100 kcal. Protein sources can be any used in the art, e.g., nonfat milk, whey protein, casein, soy protein, hydrolyzed protein, and/or amino acids. Carbohydrate sources can be any used in the art, e.g., lactose, glucose, corn syrup solids, maltodextrins, sucrose, starch, and/or rice syrup solids. Lipid sources can be any used in the art, e.g., vegetable oils such as palm oil, canola oil, corn oil, soybean oil, palmolein, coconut oil, medium chain triglyceride oil, high oleic sunflower oil, and/or high oleic safflower oil.
  • Conveniently, commercially available nutritional compositions, infant formulas, human milk supplements, or children's nutritional products can be used. For example, Enfalac, Enfamil®, Enfamil® Premature Formula, Enfamil® with Iron, Enfamil® LIPIL®, Lactofree®, Nutramigen®, Pregestimil®, and ProSobee® (available from Mead Johnson & Company, Evansville, Ind., U.S.A.) may be supplemented with suitable levels of astaxanthin and beta-carotene and used in practice of the invention.
  • If the astaxanthin and beta-carotene are administered in an infant formula, the amounts of each carotenoid in the formula may be up to about 40 nmol/g fat. In another embodiment, the amounts of each carotenoid in the formula may be within the range of about 2 nmol/g and about 35 nmol/g fat. In a particular embodiment, the amounts of each carotenoid in the formula may be within the range of about 5 nmol/g and about 30 nmol/g fat.
  • The total carotenoid blend may comprise, in an embodiment, up to about 2000 mcg/L infant formula. In other embodiments, the total carotenoid blend may comprise from about 100 to about 1500 mcg/L infant formula. In yet another embodiment, the total carotenoid blend may comprise from about 200 to about 1200 mcg/L infant formula.
  • The individual carotenoids may be present in the infant formula in an amount of from about 50 to about 1150 mcg/L, about 75 to about 230 mcg/L, or about 100 to about 200 mcg/L.
  • In some embodiments of the invention, additional components may be administered in combination with astaxanthin and beta-carotene. These additional components may include probiotics, prebiotics, or long chain polyunsaturated fatty acids (LCPUFAs). The components may be administered separately from the astaxanthin and beta-carotene or may be included as part of a nutritional composition, infant formula, human milk supplement, or children's nutritional product that contains astaxanthin, beta-carotene, and one or more additional components.
  • The term “probiotic” means a microorganism that exerts beneficial effects on the health of the host. Any probiotic known in the art may be used, provided it is suitable for combination with the other components of the supplement. For example, the probiotic may be chosen from the group consisting of Lactobacillus and Bifidobacterium. Alternatively, the probiotic can be Lactobacillus rhamnosus GG.
  • The term “prebiotic”, as used herein, means a non-digestible food ingredient that stimulates the growth and/or activity of probiotics. In this embodiment, any prebiotic known in the art may be used, provided it is suitable for combination with the other components of the supplement. In a particular embodiment, the prebiotic can be selected from the group consisting of fructo-oligosaccharide, gluco-oligosaccharide, galacto-oligosaccharide, inulin, isomalto-oligosaccharide, polydextrose, xylo-oligosaccharide, lactulose, and combinations thereof. In a particular embodiment, the prebiotic is a mixture of galacto-oligosaccharide and polydextrose.
  • In an embodiment, the total amount of prebiotics present in the nutritional composition may be from about 1.0 g/L to about 10.0 g/L of the composition. In another embodiment, the total amount of prebiotics present in the nutritional composition may be from about 2.0 g/L and about 8.0 g/L of the composition. In yet another embodiment, the total amount of prebiotics present in the nutritional composition may be about 4.0 g/L of the composition.
  • If galacto-oligosaccharide is used as a prebiotic, the amount of galacto-oligosaccharide in the nutritional composition may, in an embodiment, be within the range of from about 1.0 g/L to about 4.0 g/L. In another embodiment, the amount of galacto-oligosaccharide in the nutritional composition may be about 2.0 g/L. If polydextrose is used as a prebiotic, the amount of polydextrose in the nutritional composition may, in an embodiment, be within the range of from about 1.0 g/L to about 4.0 g/L. In another embodiment, the amount of polydextrose in the nutritional composition may be about 2.0 g/L. In a particular embodiment, galacto-oligosaccharide and polydextrose are supplemented into the nutritional composition in a total amount of about 4.0 g/L. In this embodiment, the amount of galacto-oligosaccharide may be about 2.0 g/L and the amount of polydextrose may be about 2.0 g/L.
  • While not wishing to be bound to this or any theory, it is believed that the administration of prebiotics and carotenoids may provide a synergistic effect. More specifically, it is believed that the prebiotic may alter the composition of the gut flora to provide a greater number of beneficial bacteria and fewer pathogenic bacteria, further contributing to the antimicrobial effect of the carotenoids in the present invention.
  • In yet another embodiment of the invention, LCPUFAs may be administered in combination with astaxanthin and beta-carotene. In this embodiment, the LCPUFAs may include docosahexaenoic acid (DHA), arachidonic acid (ARA), and/or eicosapentaenoic acid (EPA).
  • If administered as part of the present invention, the weight ratio of ARA:DHA may be from about 1:3 to about 9:1. In one embodiment of the present invention, this ratio is from about 1:2 to about 4:1. In yet another embodiment, the ratio is from about 2:3 to about 2:1. In one particular embodiment the ratio is about 2:1. In another particular embodiment of the invention, the ratio is about 1:1.5. In other embodiments, the ratio is about 1:1.3. In still other embodiments, the ratio is about 1:1.9. In a particular embodiment, the ratio is about 1.5:1. In a further embodiment, the ratio is about 1.47:1.
  • If administered as part of the present invention, the level of DHA may be within the range of about 0.0% and about 1.00% of fatty acids, by weight. In other embodiments, the level of DHA may be about 0.32% by weight. In some embodiments, the level of DHA may be about 0.33% by weight. In another embodiment, the level of DHA may be about 0.64% by weight. In another embodiment, the level of DHA may be about 0.67% by weight. In yet another embodiment, the level of DHA may be about 0.96% by weight. In a further embodiment, the level of DHA may be about 1.00% by weight.
  • If administered as part of the present invention, the level of ARA may be within the range of 0.0% and 0.67% of fatty acids, by weight. In another embodiment, the level of ARA may be about 0.67% by weight. In another embodiment, the level of ARA may be about 0.5% by weight. In yet another embodiment, the level of DHA may be within the range of about 0.47% and about 0.48% by weight.
  • If administered as part of the present invention, the amount of DHA may be from about 2 mg/100 kilocalories (kcal) to about 100 mg/100 kcal. In another embodiment, the amount of DHA may be from about 5 mg/100 kcal to about 75 mg/100 kcal. In yet another embodiment, the amount of DHA may be from about 15 mg/100 kcal to about 60 mg/100 kcal.
  • If administered as part of the present invention, the amount of ARA may be from about 4 mg/100 kilocalories (kcal) to about 100 mg/100 kcal. In another embodiment, the amount of ARA may be from about 10 mg/100 kcal to about 67 mg/100 kcal. In yet another embodiment, the amount of ARA may be from about 20 mg/100 kcal to about 50 mg/100 kcal. In a particular embodiment, the amount of ARA may be from about 25 mg/100 kcal to about 40 mg/100 kcal. In one embodiment, the amount of ARA is about 30 mg/100 kcal.
  • If administered as part of the present invention, the effective amount of DHA may be from about 3 mg per kg of body weight per day to about 150 mg per kg of body weight per day. In one embodiment of the invention, the amount is from about 6 mg per kg of body weight per day to about 100 mg per kg of body weight per day. In another embodiment the amount is from about 15 mg per kg of body weight per day to about 60 mg per kg of body weight per day.
  • If administered as part of the present invention, the effective amount of ARA may be from about 5 mg per kg of body weight per day to about 150 mg per kg of body weight per day. In one embodiment of this invention, the amount varies from about 10 mg per kg of body weight per day to about 120 mg per kg of body weight per day. In another embodiment, the amount varies from about 15 mg per kg of body weight per day to about 90 my per kg of body weight per day. In yet another embodiment, the amount varies from about 20 mg per kg of body weight per day to about 60 mg per kg of body weight per day.
  • If the composition of the invention is supplemented with oils containing LCPUFAs, it may be accomplished using standard techniques known in the art. For example, an equivalent amount of an oil which is normally present in a composition, such as high oleic sunflower oil, may be replaced with the LCPUFAs.
  • If utilized, the source of the LCPUFAs can be any source known in the art such as marine oil, fish oil, single cell oil, egg yolk lipid, and/or brain lipid. The LCPUFAs can be in natural form or refined form.
  • In other embodiments of the invention, astaxanthin and beta-carotene may be combined and administered to a subject for the purpose of treating or preventing any of the following: reflux, spitting up, abdominal pain, bloating, vomiting, gastric inflammation, gastritis, ulcer formation, hypertension, dyslipidemia, Type I and II diabetes, insulin sensitivity, obesity, cardiovascular disease, cancer, atherosclerosis. In other embodiments, astaxanthin and beta-carotene can be combined and administered for the purpose of improving digestion or stool consistency, modulating antioxidant enzymes, decreasing cellular and tissue oxidative stress, shifting T-helper cell Types 1 to Th2 balance, and modulating immune function.
  • In some embodiments, the invention includes a method for improving weight management in a subject comprising administering to the subject an effective amount of astaxanthin and beta-carotene. In other embodiments, the invention includes a method for preventing or treating obesity in a subject comprising administering to the subject an effective amount of astaxanthin and beta-carotene. Obesity has been linked with an inflammation of adipose tissue. In some studies, inflammation has also been identified as an early characteristic of obesity. The combination of astaxanthin and beta-carotene, in addition to their antioxidant benefits, may contribute to a reduction in inflammation, thereby reducing or preventing the onset of obesity in the present invention.
  • In an embodiment, the invention is directed to the use of a combination of astaxanthin and beta-carotene in the manufacture of an ingestible composition for inhibiting the growth of pathogenic bacterial in a subject. In another embodiment, the invention is directed to the use of a combination of astaxanthin and beta-carotene in the manufacture of an ingestible composition for inhibiting the growth of H. pylori in an infant. In yet another embodiment, the invention is directed to the use of a combination of astaxanthin and beta-carotene in the manufacture of an ingestible composition for preventing or treating a bacterial infection in a subject. In still another embodiment, the invention is directed to the use of a combination of astaxanthin and beta-carotene in the manufacture of an ingestible composition for preventing obesity in a subject.
  • The invention, in an embodiment, is also directed to a combination of astaxanthin and beta-carotene for use in inhibiting the growth of pathogenic bacteria in a subject. The invention is also directed, in an embodiment, to a combination of astaxanthin and beta-carotene for use in inhibiting the growth of H. pylori in an infant. Additionally, the invention is directed, in an embodiment, to a combination of astaxanthin and beta-carotene for use in preventing or treating a bacterial infection in a subject.
  • All references cited in this specification, including without limitation, all papers, publications, patents, patent applications, presentations, texts, reports, manuscripts, brochures, books, internet postings, journal articles, and/or periodicals are hereby incorporated by reference into this specification in their entireties. The discussion of the references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.
  • These and other modifications and variations to the present invention may be practiced by those of ordinary skill in the art, without departing from the spirit and scope of the present invention, which is more particularly set forth in the appended claims. In addition, it should be understood that aspects of the various embodiments may be interchanged in whole or in part. Furthermore, those of ordinary skill in the art will appreciate that the foregoing description is by way of example only, and is not intended to limit the invention so further described in such appended claims. Therefore, the spirit and scope of the appended claims should not be limited to the description of the preferred versions contained therein.

Claims (20)

1. A nutritional composition comprising astaxanthin, beta-carotene, galacto-oligosaccharide, and polydextrose.
2. The nutritional composition of claim 1 wherein the nutritional composition contains astaxanthin in an amount within the range of from about 50 to about 1150 mcg/L.
3. The nutritional composition of claim 1 wherein the nutritional composition contains beta-carotene in an amount within the range of from about 50 to about 1150 mcg/L.
4. The nutritional composition of claim 1 wherein the nutritional composition contains a combination of astaxanthin and beta-carotene in an amount within the range of from about 100 to about 1500 mcg/L.
5. The nutritional composition of claim 1 wherein the nutritional composition contains galacto-oligosaccharide in an amount in the range of from about 1.0 g/L to about 4.0 g/L.
6. The nutritional composition of claim 1 wherein the nutritional composition contains polydextrose in an amount within the range of from about 1.0 g/L to about 4.0 g/L.
7. The nutritional composition of claim 1 additionally comprising at least one long-chain polyunsaturated fatty acid selected from the group consisting of docosahexaenoic acid, arachidonic acid, eicosapentaenoic acid, and combinations thereof.
8. The nutritional composition of claim 1 wherein the nutritional composition is in a form selected from those consisting of an infant formula, human milk fortifier, and children's nutritional product.
9. The nutritional composition of claim 1 wherein the nutritional composition is in a form selected from those consisting of powder and liquid.
10. A method for inhibiting the growth of pathogenic bacteria in a subject comprising administering to the subject an effective amount of astaxanthin and beta-carotene.
11. The method of claim 10 wherein the effective amount of astaxanthin is within the range of about 0.01 mg and about 10 mg per kg body weight per day.
12. The method of claim 10 wherein the effective amount of astaxanthin is about 1 mg per kg body weight per day.
13. The method of claim 10 wherein the effective amount of beta-carotene is within the range of about 0.01 mg and about 10 mg per kg body weight per day.
14. The method of claim 10 wherein the effective amount of beta-carotene is about 1 mg per kg body weight per day.
15. The method according to claim 10 additionally comprising the administration of at least one prebiotic.
16. The method according to claim 15 wherein the prebiotic comprises a combination of galacto-oligosaccharide and polydextrose.
17. The method according to claim 10 wherein the pathogenic bacteria is H. pylori.
18. A method for inhibiting the growth of H. pylori in an infant comprising administering to the infant an infant formula containing an effective amount of astaxanthin and beta-carotene.
19. A method for preventing or treating a bacterial infection in a subject comprising administering to the subject the composition of claim 1.
20. A method for preventing obesity in a subject comprising administering to the subject the composition of claim 1.
US12/206,838 2007-11-07 2008-09-09 Carotenoid-containing compositions and methods Abandoned US20090118227A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/206,838 US20090118227A1 (en) 2007-11-07 2008-09-09 Carotenoid-containing compositions and methods
US13/486,760 US9072314B2 (en) 2007-11-07 2012-06-01 Carotenoid-containing compositions and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98602907P 2007-11-07 2007-11-07
US12/206,838 US20090118227A1 (en) 2007-11-07 2008-09-09 Carotenoid-containing compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/486,760 Division US9072314B2 (en) 2007-11-07 2012-06-01 Carotenoid-containing compositions and methods

Publications (1)

Publication Number Publication Date
US20090118227A1 true US20090118227A1 (en) 2009-05-07

Family

ID=40588756

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/206,838 Abandoned US20090118227A1 (en) 2007-11-07 2008-09-09 Carotenoid-containing compositions and methods
US13/486,760 Active US9072314B2 (en) 2007-11-07 2012-06-01 Carotenoid-containing compositions and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/486,760 Active US9072314B2 (en) 2007-11-07 2012-06-01 Carotenoid-containing compositions and methods

Country Status (1)

Country Link
US (2) US20090118227A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322918A1 (en) * 2009-06-22 2010-12-23 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
WO2011050474A1 (en) 2009-10-29 2011-05-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US20110136734A1 (en) * 2009-12-04 2011-06-09 Bridget Barrett-Reis Methods of Modulating Inflammation in Preterm Infants Using Carotenoids
US20110300213A1 (en) * 2010-06-02 2011-12-08 Gainer John L Oral formulations of bipolar trans carotenoids
DE102011012494A1 (en) * 2011-02-25 2012-08-30 Humana Milchunion Eg Prebiotic carbohydrate compositions
US20130095204A1 (en) * 2011-10-14 2013-04-18 Zeina Jouni Nutritional phytonutrient compositions
US8901174B2 (en) 2007-04-13 2014-12-02 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
TWI472300B (en) * 2011-12-27 2015-02-11 Abbott Lab Use of a reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life
US9604899B2 (en) 2002-02-25 2017-03-28 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP3040069A4 (en) * 2013-06-27 2017-04-12 The Doshisha Intestinal flora improving composition containing astaxanthin
US9950067B2 (en) 2005-02-24 2018-04-24 Diffusion Pharmaceuticals, LLC Trans carotenoids, their synthesis, formulation and uses
US11185523B2 (en) 2016-03-24 2021-11-30 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104422767B (en) * 2013-09-03 2017-12-08 丰益(上海)生物技术研发中心有限公司 The method that high lipid food is detected using Helicobacter.spp
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
IT202000032402A1 (en) * 2020-12-24 2022-06-24 Innobio S R L IMMUNOSTIMULATOR COMPOSITION TO INDUCE AN IMMUNE RESPONSE

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3788468A (en) * 1973-05-01 1974-01-29 Univ Virginia Process for increasing oxygen diffusivity
US3975519A (en) * 1975-06-09 1976-08-17 University Of Virginia Method for increasing the oxygen partial pressure in the bloodstream of mammals
US4046880A (en) * 1976-04-20 1977-09-06 The University Of Virginia Method of treating hypertension
US5234702A (en) * 1992-03-19 1993-08-10 Abbott Laboratories Antioxidant system for powdered nutritional products
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US5602103A (en) * 1994-02-08 1997-02-11 Nippon Mektron, Limited Cerebral function-ameliorating agent
US5635199A (en) * 1995-10-27 1997-06-03 Nestec Ltd. Support of pediatric patients
US5854015A (en) * 1995-10-31 1998-12-29 Applied Food Biotechnology, Inc. Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
US6262316B1 (en) * 1997-02-27 2001-07-17 Astacarotene Ab Oral preparation for the prophylactic and therapeutic treatment of Helicobacter sp. infection
US6261598B1 (en) * 1998-08-26 2001-07-17 Basf Aktiengesellschaft Carotenoid formulations, comprising a mixture of B-carotens, lycopene and lutein
US6265450B1 (en) * 1995-10-26 2001-07-24 Suntory Limited Anti-stress composition
US6565891B1 (en) * 2002-08-23 2003-05-20 Tsar Health Private Ltd. Nutritional supplement for children
US6617305B1 (en) * 2000-10-10 2003-09-09 Ingredient Innovations Internaitonal Stable aqueous dispersion of nutrients
US20030175364A1 (en) * 2002-03-01 2003-09-18 Jerry Newman Process for binding carotenoids to proteins and the products thereof
US20030206972A1 (en) * 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
US20030228392A1 (en) * 2002-06-06 2003-12-11 Wyeth Infant formula compositions containing lutein and zeaxanthin
US6727373B2 (en) * 1996-03-28 2004-04-27 Dsm N.V. Preparation of microbial polyunsaturated fatty acid containing oil from pasteurised biomass
US20040081628A1 (en) * 2002-10-28 2004-04-29 Gierhart Dennis L. Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US20050031736A1 (en) * 2001-12-12 2005-02-10 Nguyen Minhthy Le Infant formulas containing lutein compounds
US20050058672A1 (en) * 2003-09-14 2005-03-17 Bioderm Research Baby Care Skin Protectant Compositions for Diaper Rash
US20050069505A1 (en) * 2002-02-21 2005-03-31 Lionel Breton Orally administrable composition for the photoprotection of the skin
US20050123603A1 (en) * 2003-09-26 2005-06-09 Natural Asa Natural menaquinone 7 compositions
US6923967B1 (en) * 1998-10-16 2005-08-02 Astacarotene Ab Treatment of dyspepsia
US20050255202A1 (en) * 2002-08-14 2005-11-17 Dalziel Sean M Food partical encapsulation preserving volatiles and preventing oxidation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060106115A1 (en) * 2002-10-25 2006-05-18 Masayoshi Yamaguchi Osteogenesis promoter containing beta-cryptoxanthin as the active ingredient
US7090879B2 (en) * 2004-03-18 2006-08-15 Abbott Laboratories Nutritional formula containing select carotenoid combinations
US20070077308A1 (en) * 2003-12-18 2007-04-05 Giner Victor C Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients
US20070207132A1 (en) * 2003-10-24 2007-09-06 N.V. Nutricia Synbiotic Composition For Infants

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444205A (en) 1980-05-31 1984-04-24 University Of Strathclyde Apparatus for assessing joint mobility
CA2188983C (en) 1995-10-31 2001-02-27 Kevin M. Garnett Pure 3r-3'r stereoisomer of zeaxanthin for treating macular degeneration in humans
JP3903399B2 (en) 1997-09-25 2007-04-11 雪印乳業株式会社 Infant nutrition composition
US6914073B2 (en) 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
EP1227780A4 (en) 1999-10-28 2006-09-06 Ingredient Innovations Interna A stable aqueous dispersion of nutrients
ATE301401T1 (en) 2000-05-18 2005-08-15 Mega Healthcare As Q FOOD SUPPLEMENTS WITH VITAMINS, MINERALS AND POLYUNSATURATED FATTY ACIDS
MX246154B (en) 2001-08-23 2007-06-04 Dsm Ip Assets Bv Novel stabilized carotenoid compositions.
JP4346870B2 (en) 2002-07-05 2009-10-21 キッコーマン株式会社 Composition for inhibiting increase in blood glucose level
JP4038088B2 (en) 2002-07-30 2008-01-23 株式会社遠隔医療研究所 Muscle protein degradation inhibitor
JP2005225842A (en) 2004-02-16 2005-08-25 Riken Vitamin Co Ltd Brain function improver
CA2564066A1 (en) 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1748705B1 (en) 2004-05-18 2010-10-13 DSM IP Assets B.V. Use of beta-cryptoxanthin

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3788468A (en) * 1973-05-01 1974-01-29 Univ Virginia Process for increasing oxygen diffusivity
US3975519A (en) * 1975-06-09 1976-08-17 University Of Virginia Method for increasing the oxygen partial pressure in the bloodstream of mammals
US4046880A (en) * 1976-04-20 1977-09-06 The University Of Virginia Method of treating hypertension
US5234702A (en) * 1992-03-19 1993-08-10 Abbott Laboratories Antioxidant system for powdered nutritional products
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US5602103A (en) * 1994-02-08 1997-02-11 Nippon Mektron, Limited Cerebral function-ameliorating agent
US6265450B1 (en) * 1995-10-26 2001-07-24 Suntory Limited Anti-stress composition
US5635199A (en) * 1995-10-27 1997-06-03 Nestec Ltd. Support of pediatric patients
US5854015A (en) * 1995-10-31 1998-12-29 Applied Food Biotechnology, Inc. Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
US6727373B2 (en) * 1996-03-28 2004-04-27 Dsm N.V. Preparation of microbial polyunsaturated fatty acid containing oil from pasteurised biomass
US6262316B1 (en) * 1997-02-27 2001-07-17 Astacarotene Ab Oral preparation for the prophylactic and therapeutic treatment of Helicobacter sp. infection
US6261598B1 (en) * 1998-08-26 2001-07-17 Basf Aktiengesellschaft Carotenoid formulations, comprising a mixture of B-carotens, lycopene and lutein
US6923967B1 (en) * 1998-10-16 2005-08-02 Astacarotene Ab Treatment of dyspepsia
US6617305B1 (en) * 2000-10-10 2003-09-09 Ingredient Innovations Internaitonal Stable aqueous dispersion of nutrients
US20030206972A1 (en) * 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
US20050031736A1 (en) * 2001-12-12 2005-02-10 Nguyen Minhthy Le Infant formulas containing lutein compounds
US20050069505A1 (en) * 2002-02-21 2005-03-31 Lionel Breton Orally administrable composition for the photoprotection of the skin
US20030175364A1 (en) * 2002-03-01 2003-09-18 Jerry Newman Process for binding carotenoids to proteins and the products thereof
US20030228392A1 (en) * 2002-06-06 2003-12-11 Wyeth Infant formula compositions containing lutein and zeaxanthin
US20050255202A1 (en) * 2002-08-14 2005-11-17 Dalziel Sean M Food partical encapsulation preserving volatiles and preventing oxidation
US6565891B1 (en) * 2002-08-23 2003-05-20 Tsar Health Private Ltd. Nutritional supplement for children
US20060106115A1 (en) * 2002-10-25 2006-05-18 Masayoshi Yamaguchi Osteogenesis promoter containing beta-cryptoxanthin as the active ingredient
US20040081628A1 (en) * 2002-10-28 2004-04-29 Gierhart Dennis L. Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US20050058672A1 (en) * 2003-09-14 2005-03-17 Bioderm Research Baby Care Skin Protectant Compositions for Diaper Rash
US20050123603A1 (en) * 2003-09-26 2005-06-09 Natural Asa Natural menaquinone 7 compositions
US20070207132A1 (en) * 2003-10-24 2007-09-06 N.V. Nutricia Synbiotic Composition For Infants
US20070077308A1 (en) * 2003-12-18 2007-04-05 Giner Victor C Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients
US7090879B2 (en) * 2004-03-18 2006-08-15 Abbott Laboratories Nutritional formula containing select carotenoid combinations
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604899B2 (en) 2002-02-25 2017-03-28 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US9950067B2 (en) 2005-02-24 2018-04-24 Diffusion Pharmaceuticals, LLC Trans carotenoids, their synthesis, formulation and uses
US11278621B2 (en) 2005-02-24 2022-03-22 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
US8901174B2 (en) 2007-04-13 2014-12-02 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US20100322918A1 (en) * 2009-06-22 2010-12-23 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US11147859B2 (en) 2009-06-22 2021-10-19 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US9475830B2 (en) 2009-10-29 2016-10-25 Acasti Pharma Inc. Concentrated therapeutic phospholipid compositions
EP2493478A4 (en) * 2009-10-29 2013-02-27 Acasti Pharma Inc Concentrated therapeutic phospholipid compositions
WO2011050474A1 (en) 2009-10-29 2011-05-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US10130644B2 (en) 2009-10-29 2018-11-20 Acasti Pharma Inc. Concentrated therapeutic phospholipid compositions
EP3335713A1 (en) * 2009-10-29 2018-06-20 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
EP2493478A1 (en) * 2009-10-29 2012-09-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US10617702B2 (en) 2009-10-29 2020-04-14 Acasti Pharma Inc. Concentrated therapeutic phospholipid compositions
US20110136734A1 (en) * 2009-12-04 2011-06-09 Bridget Barrett-Reis Methods of Modulating Inflammation in Preterm Infants Using Carotenoids
US9049884B2 (en) 2009-12-04 2015-06-09 Abbott Laboratories Methods of modulating inflammation in preterm infants using carotenoids
US8974822B2 (en) * 2010-06-02 2015-03-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
US20110300213A1 (en) * 2010-06-02 2011-12-08 Gainer John L Oral formulations of bipolar trans carotenoids
CN105287473A (en) * 2010-06-02 2016-02-03 扩散药品有限公司 Oral formulations of bipolar trans carotenoids and uses thereof
US10016384B2 (en) 2010-06-02 2018-07-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
CN103124498A (en) * 2010-06-02 2013-05-29 扩散药品有限公司 Oral formulations of bipolar trans carotenoids
US11491129B2 (en) 2010-06-02 2022-11-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
DE102011012494A1 (en) * 2011-02-25 2012-08-30 Humana Milchunion Eg Prebiotic carbohydrate compositions
US20130095204A1 (en) * 2011-10-14 2013-04-18 Zeina Jouni Nutritional phytonutrient compositions
US9474766B2 (en) 2011-12-27 2016-10-25 Abbott Laboratories Use of a reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life
TWI472300B (en) * 2011-12-27 2015-02-11 Abbott Lab Use of a reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life
EP3040069A4 (en) * 2013-06-27 2017-04-12 The Doshisha Intestinal flora improving composition containing astaxanthin
US11185523B2 (en) 2016-03-24 2021-11-30 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Also Published As

Publication number Publication date
US9072314B2 (en) 2015-07-07
US20120238522A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
US9072314B2 (en) Carotenoid-containing compositions and methods
Sathasivam et al. Microalgae metabolites: A rich source for food and medicine
US20090118229A1 (en) Carotenoid-containing compositions and methods
Cao et al. Dietary astaxanthin: an excellent carotenoid with multiple health benefits
Raza et al. Beneficial effects and health benefits of Astaxanthin molecules on animal production: A review
Goswami et al. The present perspective of astaxanthin with reference to biosynthesis and pharmacological importance
EP1978821B2 (en) Method for modifying gut flora in animals
AU2013235365B2 (en) Probiotic derived non-viable material for infection prevention and treatment
Amaro et al. Microalgal compounds modulate carcinogenesis in the gastrointestinal tract
US20090118228A1 (en) Carotenoid-containing compositions and methods
JP2010111689A (en) Oral formulation for prevention and treatment of infection by helicobacter
US20090092590A1 (en) Method for improving stool characteristics in infants
RU2759600C2 (en) Use of carotenoid of microbial origin that affects composition of intestinal microorganisms
EP2575505A1 (en) Dietary formulations
JP6660289B2 (en) A composition comprising a combination of an elder extract with a strain of Lactobacillus rhamnosus
Naliyadhara et al. Interplay of dietary antioxidants and gut microbiome in human health: What has been learnt thus far?
US20170354696A1 (en) Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic
US20160151437A1 (en) Nutritional supplements for improved vision and methods of treating the same
CA2401688A1 (en) Process for production of carotenoids, xanthophylls and apo-carotenoids utilizing eukaryotic microorganisms
KR101626777B1 (en) Zeaxanthin-enriched poultry egg
AU2014278839B2 (en) A marine oil formulation comprising reservatrol or derivatives thereof for use in treating, delaying and/or preventing Alzheimer's Desease
CA2729286C (en) Nutritional compositions containing punicalagins
Hayashi et al. Effect of astaxanthin-rich extract derived from Paracoccus carotinifaciens on the status of stress and sleep in adults
López-Cervantes et al. Astaxanthin, lutein, and zeaxanthin
Shah Dietary factors in the modulation of inflammatory bowel disease activity

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRISTOL-MYERS SQUIBB COMPANY, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOUNI, ZEINA;MAKHOUL, ZEINA;REEL/FRAME:021512/0401

Effective date: 20080909

AS Assignment

Owner name: MJN RESTRUCTURING HOLDCO, INC., INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRISTOL-MYERS SQUIBB COMPANY;REEL/FRAME:022248/0663

Effective date: 20090130

Owner name: MJN RESTRUCTURING HOLDCO, INC.,INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRISTOL-MYERS SQUIBB COMPANY;REEL/FRAME:022248/0663

Effective date: 20090130

AS Assignment

Owner name: MEAD JOHNSON NUTRITION COMPANY, INDIANA

Free format text: MERGER;ASSIGNOR:MJN RESTRUCTURING HOLDCO, INC.;REEL/FRAME:022354/0768

Effective date: 20090204

Owner name: MEAD JOHNSON NUTRITION COMPANY,INDIANA

Free format text: MERGER;ASSIGNOR:MJN RESTRUCTURING HOLDCO, INC.;REEL/FRAME:022354/0768

Effective date: 20090204

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION